Autobio Diagnostics (603658) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached RMB 1.17 billion, up 3.38% year-over-year; nine-month revenue was RMB 3.38 billion, up 4.24% year-over-year.

• Net profit attributable to shareholders for Q3 was RMB 336.7 million, down 5.18% year-over-year; nine-month net profit was RMB 956.2 million, up 6.13% year-over-year.

• Basic EPS for Q3 was RMB 0.59, down 3.28% year-over-year; nine-month EPS was RMB 1.65, up 6.45% year-over-year.

Financial highlights

• Operating cash flow for the nine months was RMB 948.97 million, nearly flat year-over-year.

• Gross margin for the nine months was approximately 65.9%.

• Total assets at quarter-end were RMB 11.39 billion, down 1.42% from year-end 2023.

• Shareholders’ equity was RMB 8.40 billion, down 1.56% from year-end 2023.

• Non-recurring gains for the nine months totaled RMB 25.68 million, mainly from government grants and fair value changes.

Key financial ratios and metrics

• Weighted average ROE for the nine months was 11.06%, down 0.09 percentage points year-over-year.

• Net profit margin for the nine months was 28.3%.

• Basic and diluted EPS for the nine months were both RMB 1.65.